The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Gilteritinib in FLT3 AML

Sep 21, 2020

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub was pleased to speak to Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US, about gilteritinib for the treatment of FLT3 AML.

Gilteritinib in FLT3 AML

Gilteritinib is a FLT3 inhibitor which is FDA approved for the treatment of R/R FLT3-mutated AML. This approval was based on the phase III ADMIRAL trial, which evaluated gilteritinib vs investigator-choice chemotherapy. Data from the ADMIRAL study show that gilteritinib demonstrated a positive outcome for both of the study primary endpoints (overall survival and complete remission/complete remission with partial hematologic recovery).

Naval Daver concludes by outlining the next steps for gilteritinib in the AML setting.